Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s CEO, Greg Madison, talked to Proactive London about the strong results and growing momentum revealed in its half-year report.
Shield has executed on all three of its targets, he said, with a huge uptick in US prescriptions for anaemia treatment Accrufer feeding through into rising revenues.
Female Health (NASDAQ:FHCO) represented about 50% of total prescriptions, he adds, with roughly 1 in 5 women in the US suffering from an iron deficiency and offering a huge opportunity for Shield, he believes.
#anaemia #Accrufer #AIM #iron deficiency